Kah Woon Teoh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kah Woon Teoh has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Shaun Wen Huey Lee
School of Pharmacy, Monash University Malaysia , Jalan Lagoon Selatan, Bandar Sunway, 47500 Subang Jaya, Selangor
5 shared publications - Wing Loong Cheong
Monash University Malaysia
3 shared publications Choon Ming Ng
School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500, Selangor, Malaysia
2 shared publicationsChun Wie Chong
School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500, Selangor, Malaysia
2 shared publications- Chun Wie Chong
School of Pharmacy, Monash University Malaysia, Subang Jaya, Malaysia
2 shared publications J Simon Bell
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia
2 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Cambridge University Press (CUP) in Primary Health Care Research & Development
- Vol. 27, e104
Facilitators and barriers to implementing a digital health-supported, community pharmacy-based prediabetes management program (PRIME program) in Malaysia: a qualitative study of participants’ and pharmacists’ perspectives
Aim: This study aims to evaluate the facilitators and barriers to the implementation, adoption, and participation of these programs. Background: The Prediabetes Intervention, Management, and Evaluation (PRIME) program is an initiative that integrates digital health tools with community pharmacy services to encourage lifestyle behaviour changes among participants with prediabetes. While PRIME demonstrates effectiveness in clinical outcomes, the integration of such programs into community pharmacy services remains limited. Methods: In-depth focus group discussions and one-on-one interviews were conducted with participants and pharmacists who were involved in PRIME. The semi-structured interviews focused on the experiences and perceptions of the implementation of PRIME and its influence on behaviour change. All audio-recorded interviews were transcribed, coded, and analysed using thematic analysis techniques, leading to the development of major themes. Findings: Seven focus groups and twenty interviews were conducted among 37 participants and 10 pharmacists. Five themes were developed: 1) Intrinsic motivations towards better health; 2) Influence of rapport building; 3) Improved convenience to healthcare access; 4) Resource and support; and 5) Innovation with digital health. Key barriers were related to the use of digital health tools (technical difficulties, lacking engaging functionalities) and resources (workload management, availability of prediabetes-specific guidelines). The participants perceived the blended approach of in-person support with technology-assisted interventions in PRIME as an effective way to build healthier lifestyles. While community pharmacy-based prediabetes management programs like PRIME can be effective in driving healthier lifestyles, several barriers hinder their broader adoption. Addressing these barriers could enhance the implementation and uptake of these programs.
- 18 September 2026
- Published by Cambridge University Press (CUP) in Primary Health Care Research & Development
- Vol. 27, e104
Open AccessFacilitators and barriers to implementing a digital health-supported, community pharmacy-based prediabetes management program (PRIME program) in Malaysia: a qualitative study of participants’ and pharmacists’ perspectives
Aim: This study aims to evaluate the facilitators and barriers to the implementation, adoption, and participation of these programs. Background: The Prediabetes Intervention, Management, and Evaluation (PRIME) program is an initiative that integrates digital health tools with community pharmacy services to encourage lifestyle behaviour changes among participants with prediabetes. While PRIME demonstrates effectiveness in clinical outcomes, the integration of such programs into community pharmacy services remains limited. Methods: In-depth focus group discussions and one-on-one interviews were conducted with participants and pharmacists who were involved in PRIME. The semi-structured interviews focused on the experiences and perceptions of the implementation of PRIME and its influence on behaviour change. All audio-recorded interviews were transcribed, coded, and analysed using thematic analysis techniques, leading to the development of major themes. Findings: Seven focus groups and twenty interviews were conducted among 37 participants and 10 pharmacists. Five themes were developed: 1) Intrinsic motivations towards better health; 2) Influence of rapport building; 3) Improved convenience to healthcare access; 4) Resource and support; and 5) Innovation with digital health. Key barriers were related to the use of digital health tools (technical difficulties, lacking engaging functionalities) and resources (workload management, availability of prediabetes-specific guidelines). The participants perceived the blended approach of in-person support with technology-assisted interventions in PRIME as an effective way to build healthier lifestyles. While community pharmacy-based prediabetes management programs like PRIME can be effective in driving healthier lifestyles, several barriers hinder their broader adoption. Addressing these barriers could enhance the implementation and uptake of these programs.
- Open Access
- 7 October 2025
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 22 (2) , 272-282
A digital health-supported community pharmacy-based lifestyle intervention program for overweight or obese adults with prediabetes, the PRediabetes Intervention, Management and Evaluation (PRIME) Program: A cluster randomized controlled trial
- 7 October 2025
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 22 (2) , 272-282
Open AccessA digital health-supported community pharmacy-based lifestyle intervention program for overweight or obese adults with prediabetes, the PRediabetes Intervention, Management and Evaluation (PRIME) Program: A cluster randomized controlled trial
- Open Access
- 24 March 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (6) , 3324-3334
A cost‐effectiveness analysis alongside trial of a digital health‐supported and community pharmacy‐based prediabetes management programme ( PRIME Programme) in Malaysia
Aims: This study assessed the cost‐effectiveness of a digital health‐supported and community pharmacy‐based lifestyle intervention (PRIME) programme for individuals with prediabetes in Malaysia over a 6‐month period. Materials and Methods: A trial‐based cost‐effectiveness study with a 6‐month time horizon was conducted. Ninety‐one participants (intervention, n = 46; usual care, n = 45) across 13 community pharmacies were included. The intervention group received in‐depth counselling from pharmacists, in‐app prediabetes education modules and peer support, while the usual care group received counselling based on pharmacists' usual practice. The primary outcome was quality‐adjusted life years (QALY). Incremental cost‐effectiveness ratios (ICER) per QALY gained of the intervention were compared with usual care from healthcare and societal perspectives. Non‐parametric bootstrapping was used to examine uncertainty. Results: At 6months, the QALY achieved was 0.467 (95% CI 0.456 to 0.479) in the intervention group and 0.466 (95% CI 0.451 to 0.482) in the usual care group, resulting in a net gain of 0.005 QALY (95% CI −0.017 to 0.026) in the intervention group. The incremental healthcare and societal costs were US$6.10 (95% CI $5.33 to $6.88) and $10.69 (95% CI $6.03 to $15.35), respectively. From a healthcare perspective, the ICER per QALY gained was $1354, with a probability of 69.2% being cost‐effective, while the corresponding figures were $2371 and 67.7% from a societal perspective. Results were below the willingness‐to‐pay threshold at $11 845 and were robust to sensitivity analyses. Conclusion: A community pharmacy‐based and digital health‐supported lifestyle intervention to manage prediabetes may be cost‐effective compared with usual care in Malaysia over a 6‐month period.
- 24 March 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (6) , 3324-3334
Open AccessA cost‐effectiveness analysis alongside trial of a digital health‐supported and community pharmacy‐based prediabetes management programme ( PRIME Programme) in Malaysia
Aims: This study assessed the cost‐effectiveness of a digital health‐supported and community pharmacy‐based lifestyle intervention (PRIME) programme for individuals with prediabetes in Malaysia over a 6‐month period. Materials and Methods: A trial‐based cost‐effectiveness study with a 6‐month time horizon was conducted. Ninety‐one participants (intervention, n = 46; usual care, n = 45) across 13 community pharmacies were included. The intervention group received in‐depth counselling from pharmacists, in‐app prediabetes education modules and peer support, while the usual care group received counselling based on pharmacists' usual practice. The primary outcome was quality‐adjusted life years (QALY). Incremental cost‐effectiveness ratios (ICER) per QALY gained of the intervention were compared with usual care from healthcare and societal perspectives. Non‐parametric bootstrapping was used to examine uncertainty. Results: At 6months, the QALY achieved was 0.467 (95% CI 0.456 to 0.479) in the intervention group and 0.466 (95% CI 0.451 to 0.482) in the usual care group, resulting in a net gain of 0.005 QALY (95% CI −0.017 to 0.026) in the intervention group. The incremental healthcare and societal costs were US$6.10 (95% CI $5.33 to $6.88) and $10.69 (95% CI $6.03 to $15.35), respectively. From a healthcare perspective, the ICER per QALY gained was $1354, with a probability of 69.2% being cost‐effective, while the corresponding figures were $2371 and 67.7% from a societal perspective. Results were below the willingness‐to‐pay threshold at $11 845 and were robust to sensitivity analyses. Conclusion: A community pharmacy‐based and digital health‐supported lifestyle intervention to manage prediabetes may be cost‐effective compared with usual care in Malaysia over a 6‐month period.
- Open Access
A digital health-supported and community pharmacy-based lifestyle intervention program for adults with pre-diabetes: a study protocol for a cluster randomised controlled trial
Introduction Pre-diabetes indicates an elevated risk of developing type-2 diabetes and presents a window for preventive actions. The Pre-diabetes Intervention, Management and Evaluation (PRIME) programme is a community pharmacy-based pre-diabetes management programme that uses a mobile application for self-monitoring and pre-diabetes education, aiming to promote lifestyle changes among participants with pre-diabetes. Methods and analysis This is a protocol for a cluster randomised controlled trial that aims to evaluate the impact of the PRIME programme on participants’ clinical outcomes and explore participants’ and pharmacists’ views towards its implementation. This protocol describes the development of the PRIME programme and mobile app, its feasibility and implementation in community pharmacy settings. 16 pharmacies from two states in Malaysia will be randomised to the intervention arm or standard care. The study will include overweight or obese adults with pre-diabetes. During each follow-up visit at the pharmacy, intervention participants will receive in-depth counselling from pharmacists after reviewing their self-monitoring data recorded in the PRIME app. They will also receive pre-diabetes education through the app and join a peer support chatgroup. The primary clinical outcome includes changes in body weight at 6 months, while the secondary clinical outcomes include changes in blood glucose profile, lipid profile, blood pressure and adiposity measures. The sustainability of the PRIME programme will be accessed using a follow-up questionnaire, while participants’ engagement with the intervention will be evaluated using attendance rate and the app data. Focus group discussions and one-to-one interviews will be conducted for process evaluation. This study will inform the impact of community pharmacists-led digital health intervention in pre-diabetes management. Ethics and dissemination This study has been registered with clinicaltrials.gov (NCT04832984) and approved by the Monash University Human Research Ethics Committee (Project ID: 27512). Trial registration number clinicaltrials.gov (NCT04832984).
Open AccessA digital health-supported and community pharmacy-based lifestyle intervention program for adults with pre-diabetes: a study protocol for a cluster randomised controlled trial
Introduction Pre-diabetes indicates an elevated risk of developing type-2 diabetes and presents a window for preventive actions. The Pre-diabetes Intervention, Management and Evaluation (PRIME) programme is a community pharmacy-based pre-diabetes management programme that uses a mobile application for self-monitoring and pre-diabetes education, aiming to promote lifestyle changes among participants with pre-diabetes. Methods and analysis This is a protocol for a cluster randomised controlled trial that aims to evaluate the impact of the PRIME programme on participants’ clinical outcomes and explore participants’ and pharmacists’ views towards its implementation. This protocol describes the development of the PRIME programme and mobile app, its feasibility and implementation in community pharmacy settings. 16 pharmacies from two states in Malaysia will be randomised to the intervention arm or standard care. The study will include overweight or obese adults with pre-diabetes. During each follow-up visit at the pharmacy, intervention participants will receive in-depth counselling from pharmacists after reviewing their self-monitoring data recorded in the PRIME app. They will also receive pre-diabetes education through the app and join a peer support chatgroup. The primary clinical outcome includes changes in body weight at 6 months, while the secondary clinical outcomes include changes in blood glucose profile, lipid profile, blood pressure and adiposity measures. The sustainability of the PRIME programme will be accessed using a follow-up questionnaire, while participants’ engagement with the intervention will be evaluated using attendance rate and the app data. Focus group discussions and one-to-one interviews will be conducted for process evaluation. This study will inform the impact of community pharmacists-led digital health intervention in pre-diabetes management. Ethics and dissemination This study has been registered with clinicaltrials.gov (NCT04832984) and approved by the Monash University Human Research Ethics Committee (Project ID: 27512). Trial registration number clinicaltrials.gov (NCT04832984).
- Open Access
- 15 February 2023
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 11 (1) , e003203
Knowledge, attitude, and practice toward pre-diabetes among the public, patients with pre-diabetes and healthcare professionals: a systematic review
The prevalence of pre-diabetes is increasing globally, affecting an estimated 552 million people by 2030. While lifestyle interventions are the first line of defense against progression toward diabetes, information on barriers toward pre-diabetes management and how to overcome these barriers are scarce. This systematic review describes the publics’ and healthcare professionals’ knowledge, attitude and practice (KAP) toward pre-diabetes and determines the barriers toward pre-diabetes management. A systematic search for studies examining KAP towards pre-diabetes was conducted in six databases from inception to September 2022. Studies that quantitatively assessed at least two KAP elements using questionnaires were included. The quality of studies was assessed using the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. Barriers and enablers were identified and mapped onto the Capability, Motivation, and Behaviour model to identify factors that influence behavior change. Twenty-one articles that surveyed 8876 participants were included in this review. Most of the reviews (n=13) were directed to healthcare professionals. Overall, positive attitudes toward diabetes prevention efforts were observed, although there were still knowledge deficits and poor behavior toward pre-diabetes management. Barriers and enablers were detected at patients (eg, goals and intention), healthcare professionals (eg, clinical judgement) and system (eg, access and resources) levels. The use of different survey instruments to assess KAP prevented a head-to-head comparison between studies. Most studies conducted among patients were from middle-income countries, while among healthcare professionals (HCPs) were from high-income countries, which may produce some biasness. Nevertheless, the development of pre-diabetes intervention should focus on: (1) increasing knowledge on pre-diabetes and its management; (2) imparting practical skills to manage pre-diabetes; (3) providing resources for lifestyle management; (4) improving the accessibility of lifestyle management programs; and (5) other HCPs and human support to pre-diabetes management.
- 15 February 2023
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 11 (1) , e003203
Open AccessKnowledge, attitude, and practice toward pre-diabetes among the public, patients with pre-diabetes and healthcare professionals: a systematic review
The prevalence of pre-diabetes is increasing globally, affecting an estimated 552 million people by 2030. While lifestyle interventions are the first line of defense against progression toward diabetes, information on barriers toward pre-diabetes management and how to overcome these barriers are scarce. This systematic review describes the publics’ and healthcare professionals’ knowledge, attitude and practice (KAP) toward pre-diabetes and determines the barriers toward pre-diabetes management. A systematic search for studies examining KAP towards pre-diabetes was conducted in six databases from inception to September 2022. Studies that quantitatively assessed at least two KAP elements using questionnaires were included. The quality of studies was assessed using the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. Barriers and enablers were identified and mapped onto the Capability, Motivation, and Behaviour model to identify factors that influence behavior change. Twenty-one articles that surveyed 8876 participants were included in this review. Most of the reviews (n=13) were directed to healthcare professionals. Overall, positive attitudes toward diabetes prevention efforts were observed, although there were still knowledge deficits and poor behavior toward pre-diabetes management. Barriers and enablers were detected at patients (eg, goals and intention), healthcare professionals (eg, clinical judgement) and system (eg, access and resources) levels. The use of different survey instruments to assess KAP prevented a head-to-head comparison between studies. Most studies conducted among patients were from middle-income countries, while among healthcare professionals (HCPs) were from high-income countries, which may produce some biasness. Nevertheless, the development of pre-diabetes intervention should focus on: (1) increasing knowledge on pre-diabetes and its management; (2) imparting practical skills to manage pre-diabetes; (3) providing resources for lifestyle management; (4) improving the accessibility of lifestyle management programs; and (5) other HCPs and human support to pre-diabetes management.